The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

Tirzepatide acts on GLP-1 plus glucose-dependent insulinotropic ... investors who buy this stock at recent prices could ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

The popularity led to sky-high prices, supply shortages and ... used the medication to reach their goal weight and hoped to ...

Henry Meds offers compounded tirzepatide, which may be prescribed after completing an online medical form and telehealth call with one of the platform’s physicians. Unlike other platforms, Henry ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...